Suggested Readings
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
Bruce IN, et al. Lupus Sci Med. 2023;10(1):e000761.
Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study.
Furie R, et al. Clin J Am Soc Nephrol. 2022;17(11):1620-1630.
Anifrolumab in lupus nephritis: results from second-year extension of a randomized phase II trial.
Jayne D, et al. Lupus Sci Med. 2023;10(2):e000910.
A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus.
Kalunian KC, et al. Arthritis Rheumatol. 2023;75(2):253-265.
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
Morand EF, et al. Lancet Rheum. 2022;4(4):E282-E292.
Trial of anifrolumab in active systemic lupus erythematosus.
Morand EF, et al. N Engl J Med. 2020;382(3):211-221.
Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study.
Ruiz-Arruza I, et al. Arthritis Care Res. 2018;70(4):582-591.
Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus.
Wallace DJ, et al. Arthritis Rheumatol. 2019;71(7):1125-1134.
Linked Resources
DISEASE MANAGEMENT GUIDELINES
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A, et al. Ann Rheum Dis. 2024;83(1):15-29.
KDIGO 2024 clinical practice guideline for the management of lupus nephritis.
Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. Kidney Int. 2024;105(suppl 1):S1-S69.
PATIENT RESOURCES
American College of Rheumatology
Lupus Foundation of America
Lupus Research Alliance
Related activities


Webcast Series
0.50 AMA PRA
Highlights of the 2023 EULAR Guideline Updates in SLE
What You Need to Know
Faculty: | Eric Morand, MBBS (Hons), PhD, FRACP |
Release: | 02/27/2024 |
Expiration: | 02/27/2025 |


0.50 AMA PRA
Recommendations For Identifying and Achieving Early Treatment Targets
Using Steroid-Sparing Regimens For Moderate to Severe SLE
Faculty: | Eric Morand, MBBS (Hons), PhD, FRACP; Marta Mosca, MD, PhD |
Release: | 03/14/2024 |
Expiration: | 03/14/2025 |


0.75 AMA PRA
New Guidelines on Biologics
for SLE Management
Faculty: | Eric Morand, MBBS (Hons), PhD, FRACP; Marta Mosca, MD, PhD |
Release: | 03/28/2024 |
Expiration: | 03/28/2025 |